NCT04494646View on ClinicalTrials.gov

BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

January 8, 2021

Study Completion Date

January 8, 2021

Conditions
Covid19
Interventions
DRUG

Bardoxolone Methyl

Once-daily administration of bardoxolone methyl (20mg)

DRUG

Placebo

Once-daily administration of matching placebo

Trial Locations (8)

10016

NYU Bellevue Hospital Center, New York

NYU Langone Health, New York

11220

NYU Langone Hospital - Brooklyn, Brooklyn

11235

Coney Island Hospital, Brooklyn

11373

Elmhurst Hospital Center, Elmhurst

11501

NYU Winthrop Hospital, Mineola

62769

HSHS St. John's Hospital (Prairie Education and Research Cooperative), Springfield

62794

SIU School of Medicine, Springfield

All Listed Sponsors
collaborator

Reata Pharmaceuticals, Inc.

INDUSTRY

lead

NYU Langone Health

OTHER

NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) | Biotech Hunter | Biotech Hunter